Connor, Clark & Lunn Investment Management Ltd. Passage Bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.96 - $1.88 $552 - $1,082	576 Added 0.7%	82,895 $79,000
Q4 2022 Feb 10, 2023	SELL	$1.06 - $1.48 $5,843 - $8,159	-5,513 Reduced 6.28%	82,319 $113,000
Q3 2022 Nov 10, 2022	BUY	$1.22 - $2.48 $57,963 - $117,827	47,511 Added 117.83%	87,832 $110,000
Q2 2022 Aug 05, 2022	SELL	$1.63 - $3.46 $9,750 - $20,697	-5,982 Reduced 12.92%	40,321 $95,000
Q1 2022 May 12, 2022	BUY	$2.66 - $6.49 $61,153 - $149,205	22,990 Added 98.61%	46,303 $144,000
Q4 2021 Feb 10, 2022	BUY	$6.24 - $10.2 $145,473 - $237,792	23,313 New	23,313 $148,000

Others Institutions Holding PASG

# of Institutions

Shares Held

38.7M

Call Options Held

7.7K

Put Options Held

Orbimed Advisors LLC San Diego, CA

9.82M
Shares

$5.8 Million
0.16% of portfolio
Lynx1 Capital Management LP San Juan, PR

8.43M
Shares

$4.97 Million
2.11% of portfolio
Vestal Point Capital, LP New York, NY

6.1M
Shares

$3.6 Million
0.32% of portfolio
New Leaf Venture Partners, L.L.C. New York, NY

2.5M
Shares

$1.47 Million
1.8% of portfolio
Erste Asset Management Gmb H Vienna, C4

2.46M
Shares

$1.45 Million
0.02% of portfolio

View Full List

About Passage BIO, Inc.

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $32.1M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

More about PASG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account